Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
7.00    -0.02 (-0.27%)
Bid:
6.50
Ask:
7.50
Spread: 1.00 (15.385%)
Market Cap: £473.67m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Holding(s) in Company

3 May 2005 15:04

Allergy Therapeutics PLC03 May 2005 Schedule 10 NOTIFICATION OF MAJOR INTERSTS IN SHARES 1. Name of Company Allergy Therapeutics plc 2. Name of shareholder having a major interest Fidelity International Limited 3. Please state whether notification indicates that it is inrespect of holding of the shareholder names in 2 above or in respect of anon-beneficial interest or in the case of children under the age of 18 Non-beneficial interest 4. Name of the registered holder(s) and, if more than oneholder, the number of share held by each of them Nominee/registered name Share held Management CompanyJP Morgan, Bournemouth 922,100 Fidelity Inv Services LtdBank of New York, Brussels 359,662 Fidelity Pension Mgmnt(FPM)Bankers Trust London 135,700 FPMCITIBANK London 128,400 FPMClydesdale Bank plc 71,900 FPMJP Morgan, Bournemouth 288,500 FPMMellon Bank 325,400 FPMMidland Securities Services 74,300 FPMNorthern Trust London 618,500 FPMState STR BK and TR Co London 227,084 FPMBrown Bros Harrimn Ltd LUX 650,000 FPMBank of New York, Brussels 81,900 FIL 5. Number of shares/amount of stock acquired 425,586 6. Percentage of issued class 0.68% 7. Number of shares/amount of stock disposed - 8. Percentage of issued class - 9. Class of security Ordinary shares 10. Date of transaction Not notified 11. Date company informed 29th April 2005 12. Total holding following this notification 3,883,446 13. Total percentage holding of issued class following thisnotification 6.17% 14. Any additional items Notifiable interest also comprises of Mr.Edward C. Johnson 3d A principalShareholder of Fidelity International Limited 15. Name of contact and telephone number for queries Ian Postlethwaite - 01903 844721 16. Name and signature of authorised company official responsiblefor make this notification Ian Postlethwaite Date of notification 3rd May 2005 The FSA does not give any express or implied warranty as to the accuracy of thisdocument or material and does not accept liability for error or omission. TheFSA is not liable for any damages (including, without limitation, damages forloss of business or loss of profits) arising in contract, tort or otherwise fromthe use of or inability to use this document, or any material contained in it,or from any action or decision taken as a result of using this document or anysuch material. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Jun 20267:00 amRNSLong Term Incentive Awards
12th Jun 20267:00 amRNS-RAllergy Therapeutics to present at EAACI 2026
31st Mar 20267:00 amRNSInterim Results for six months ended 31 Dec 2025
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
4th Mar 20267:00 amRNSPositive Biomarker Results from PROTECT Trial
26th Feb 20267:00 amRNS-RAllergy Therapeutics presents progress at AAAAI
23rd Feb 20267:51 amRNSUpdate on funding and total voting rights
30th Jan 20268:22 amRNSChief Strategy Officer and Board appointments
29th Jan 20262:13 pmRNSResult of Annual General Meeting
28th Jan 20264:48 pmRNSGrant of Options under Long Term Incentive Scheme
19th Jan 20267:00 amRNSHalf Year Trading Update
6th Jan 20267:00 amRNSNotice of 2025 Annual General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
16th Dec 20257:00 amRNSGrassmuno® marketing authorisation in Germany
12th Dec 20257:00 amRNSAuthority for allotment of New Shares
11th Dec 20257:00 amRNSPrelim Results and publication of Annual Report
9th Dec 20257:00 amRNSPrimary Safety Endpoint Met in PROTECT trial
6th Nov 20257:22 amRNSCompany to Evaluate Dual Listing on HKEX
30th Oct 20257:00 amRNSG308 Phase III Year 2 Patient Screening Starts
29th Oct 20257:00 amRNSWarrant Exercise and Paydown of Debt
16th Oct 20257:00 amRNSFurther progress in Phase I/IIa PROTECT trial
31st Jul 20257:00 amRNS-RGrass MATA MPL Publications in Allergy Journal
21st Jul 20257:00 amRNSTrading update for the year ended 30 June 2025
11th Jul 20257:00 amRNSPDMR Dealings
13th Jun 20257:00 amRNS-RAllergy Therapeutics presents findings at EAACI
10th Jun 20257:04 amRNS-REAACI Early Career Research Award
31st Mar 20257:00 amRNSInterim Results for six months ended 31 Dec 2024
27th Mar 20257:00 amRNSAdvancement to final phase of PROTECT trial
3rd Mar 20257:00 amRNSNew Executive Long Term Incentive Awards
27th Feb 20257:00 amRNS-RPresentations at 2025 AAAAI / WAO Joint Congress
17th Feb 20257:00 amRNSGrass MATA MPL Phase III data published in Allergy
14th Feb 20257:00 amRNSGrant of Options
28th Jan 20257:00 amRNSHalf Year Trading update
22nd Jan 20257:00 amRNSPDMR Dealing and Total Voting Rights
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20241:41 pmRNSExercise of Options and Total Voting Rights
17th Dec 20244:19 pmRNSBlock Listing Interim Review
16th Dec 20243:33 pmRNSResult of Annual General Meeting
4th Dec 20247:00 amRNSPositive Interim Data from PROTECT Trial
27th Nov 20247:00 amRNSFirst Patient Dosed in G308 Paediatric Trial
25th Nov 20247:00 amRNSSubmission of MAA for Grass MATA MPL
21st Nov 20247:00 amRNSNotice of 2024 Annual General Meeting
6th Nov 20247:00 amRNSAudited Preliminary Results 2024
21st Oct 20247:00 amRNSCommencement of Phase III Paediatric Trial
16th Oct 20247:00 amRNSUpdate on funding
1st Oct 20247:00 amRNSUpdate on funding and preliminary results
17th Sep 20247:00 amRNSProgression of patient cohorts in PROTECT Trial
27th Aug 20247:00 amRNSUpdate on funding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.